Zobrazeno 1 - 10
of 311
pro vyhledávání: '"ROBERT T. CHEN"'
Autor:
Deborah A. Gust, Sanjyot Shinde, Sherri L. Pals, Felicia Hardnett, Robert T. Chen, Travis Sanchez
Publikováno v:
Journal of Epidemiology and Global Health, Vol 3, Iss 1 (2019)
There is increased emphasis on physician attention to the overall health and wellness of homosexual and bisexual men, though little is known about the health-related attitudes of these groups. This study determined factors associated with the health
Externí odkaz:
https://doaj.org/article/a16b770073d54ca1b3f4c5c6d8b532e5
Autor:
Deborah A. Gust, Sanjyot Shinde, Sherri L. Pals, Felicia Hardnett, Robert T. Chen, Travis Sanchez
Publikováno v:
Journal of Epidemiology and Global Health, Vol 3, Iss 4 (2019)
Externí odkaz:
https://doaj.org/article/cba4f40a85af4eb8951842e27e085220
Autor:
Rennatus Mdodo DrPH, MS, Deborah Gust PhD, Fredrick O. Otieno DCMS, MPH, Eleanor McLellan-Lemal MA, Robert T. Chen MD, MA, Charles LeBaron MD, Felicia Hardnett MS, Kyle Turner MS, Richard Ndivo BSc, Clement Zeh PhD, Taraz Samandari MD, PhD, Lisa A. Mills MD
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 15 (2016)
Cost-effective HIV prevention programs should target persons at high risk of HIV acquisition. We conducted an observational HIV incidence cohort study in Kisumu, Kenya, where HIV prevalence is triple that of the national rate. We used referral and ve
Externí odkaz:
https://doaj.org/article/0f0e2d9cc12c45f8b1bf3b9d3aa5ffab
Autor:
Michael Martin, Leisa H. Weld, Theodore F. Tsai, Gina T. Mootrey, Robert T. Chen, Manette Niu, Martin S. Cetron
Publikováno v:
Emerging Infectious Diseases, Vol 7, Iss 6, Pp 945-951 (2001)
In 1998, the Centers for Disease Control and Prevention was notified of severe illnesses and one death, temporally associated with yellow fever (YF) vaccination, in two elderly U.S. residents. Because the cases were unusual and adverse events followi
Externí odkaz:
https://doaj.org/article/f050b780173c49c4aabfece93acf17a9
Autor:
Rebecca E Chandler, James Milligan, Emmanuelle Espie, Katharina Hartmann, Madhava Ram Balakrishnan, Daniel Brasseur, Philip Bryan, Corinne Jouquelet-Royer, Linda Nesbitt, Shanthi Pal, Alexander Precioso, Paulo Takey, Robert T Chen
Publikováno v:
BMJ Global Health, Vol 9, Iss 3 (2024)
This analysis describes the successes, challenges and opportunities to improve global vaccine safety surveillance as observed by the Vaccine Safety Working Group from its role as a platform of exchange for stakeholders responsible for monitoring the
Externí odkaz:
https://doaj.org/article/e72c4727d6544d8c81ab20090652d1a9
Autor:
Robert T. Chen
Publikováno v:
Emerging Infectious Diseases, Vol 13, Iss 11, Pp 1802-1802 (2007)
Externí odkaz:
https://doaj.org/article/c93f65d4d4bf4d759335151521d56b26
Autor:
Patrick L F Zuber, Robert T Chen, Marion Gruber, David C Kaslow, Brigitte K Giersing, Martin H Friede
Publikováno v:
BMJ Global Health, Vol 6, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/dd03b67736bb4ee8b790af898f7c70dc
Autor:
Brett, Leav, Walter, Straus, Phil, White, Alison, Leav, Tashawnee, Gaines, Grace, Maggiacomo, Denny, Kim, Emily R, Smith, Marc, Gurwith, Robert T, Chen
Publikováno v:
Vaccine. 40:5275-5293
The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group has prepared standardized templates to describe the key considerations for the benefit-risk assessment of several vaccine platform technologies, incl
Autor:
Pedro M Folegatti, Daniel Jenkin, Susan Morris, Sarah Gilbert, Denny Kim, James S. Robertson, Emily R. Smith, Emalee Martin, Marc Gurwith, Robert T. Chen
Publikováno v:
Vaccine. 40:5248-5262
Replication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient a
The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group has prepared standardized templates to describe the key considerations for the benefit-risk assessment of several vaccine platform technologies, incl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35c9c9b5cac525998f35cbf554a67dc8